[Suppressive effect of roxithromycin on TARC production in epidermal cells].
Komine
Mayumi
M
Kakinuma
Homare
H
Tamaoki
Kunihiko
K
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D002478:Cells, Cultured; D054414:Chemokine CCL17; D019742:Chemokines, CC / Q000096:biosynthesis*; D003864:Depression, Chemical; D004305:Dose-Response Relationship, Drug; D000078404:Epidermal Cells; D004817:Epidermis / Q000378:metabolism*; D006801:Humans; D007371:Interferon-gamma / Q000037:antagonists & inhibitors; D016328:NF-kappa B / Q000378:metabolism; D015575:Roxithromycin / Q000494:pharmacology*; D018418:Th2 Cells; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
D000900:Anti-Bacterial Agents; C106230:CCL17 protein, human; D054414:Chemokine CCL17; D019742:Chemokines, CC; D016328:NF-kappa B; D014409:Tumor Necrosis Factor-alpha; D015575:Roxithromycin; D007371:Interferon-gamma